Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-25-044787
Filing Date
2025-03-26
Accepted
2025-03-26 07:44:49
Documents
99
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K mreo-20241231.htm   iXBRL 10-K 3715450
2 EX-10.31 mreo-ex10_31.htm EX-10.31 309463
3 EX-10.32 mreo-ex10_32.htm EX-10.32 752438
4 EX-23.1 mreo-ex23_1.htm EX-23.1 4057
5 EX-31.1 mreo-ex31_1.htm EX-31.1 24330
6 EX-31.2 mreo-ex31_2.htm EX-31.2 24386
7 EX-32.1 mreo-ex32_1.htm EX-32.1 7890
8 EX-32.2 mreo-ex32_2.htm EX-32.2 7858
9 GRAPHIC img40598589_0.jpg GRAPHIC 887941
  Complete submission text file 0000950170-25-044787.txt   17685458

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT mreo-20241231.xsd EX-101.SCH 1813179
102 EXTRACTED XBRL INSTANCE DOCUMENT mreo-20241231_htm.xml XML 2707811
Mailing Address ONE CAVENDISH PLACE FOURTH FLOOR LONDON X0 W1G0QF
Business Address ONE CAVENDISH PLACE FOURTH FLOOR LONDON X0 W1G0QF 4403330237300
Mereo BioPharma Group plc (Filer) CIK: 0001719714 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-38452 | Film No.: 25770204
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)